VCAM1 and neoplasm: Furthermore, compared to nonresponders, responders to anti‐PD1 monotherapy had increased VCAM1+ STING+ vessel counts found in close vicinity to CD8+ T‐cells and the fraction of effector PD1+/GrzB+ CD8+ T‐cells, particularly at the tumor–stroma interface.